Comment on ‘Drug survival, effectiveness and safety of risankizumab for moderate-to-severe psoriasis for up to 4 years’: clarifying drug survival metrics and capturing joint outcomes

Comment on ‘Drug survival, effectiveness and safety of risankizumab for moderate-to-severe psoriasis for up to 4 years’ by Mastorino et al. Clarifying the handling of nonmedical discontinuations and providing additional insight into outcomes among patients with concomitant psoriatic arthritis could further strengthen the external comparability and clinical interpretability of the reported drug survival.